WO2001035953A3 - Exercise and muscle enhancement formulations - Google Patents
Exercise and muscle enhancement formulations Download PDFInfo
- Publication number
- WO2001035953A3 WO2001035953A3 PCT/US2000/032307 US0032307W WO0135953A3 WO 2001035953 A3 WO2001035953 A3 WO 2001035953A3 US 0032307 W US0032307 W US 0032307W WO 0135953 A3 WO0135953 A3 WO 0135953A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- creatine
- arginine
- muscle
- sustained
- exercise
- Prior art date
Links
- 210000003205 muscle Anatomy 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 12
- 229960003624 creatine Drugs 0.000 abstract 6
- 239000006046 creatine Substances 0.000 abstract 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 239000004475 Arginine Substances 0.000 abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
- 235000009697 arginine Nutrition 0.000 abstract 3
- 102000004420 Creatine Kinase Human genes 0.000 abstract 2
- 108010042126 Creatine kinase Proteins 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 2
- 229930064664 L-arginine Natural products 0.000 abstract 2
- 235000014852 L-arginine Nutrition 0.000 abstract 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- 229930182816 L-glutamine Natural products 0.000 abstract 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 230000000386 athletic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960002173 citrulline Drugs 0.000 abstract 1
- 229960004826 creatine monohydrate Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229960002743 glutamine Drugs 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 229960003104 ornithine Drugs 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 229950007002 phosphocreatine Drugs 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 230000024883 vasodilation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed are exercise and muscle enhancing formulations of creatine with an insulin modulating agent such as arginine. Also included are precursers, biological equivalents, or intermediate products of arginine such as L-citrulline, L-ornithine, L-glutamine, or L-lysine, their salts, esters, peptides, dipeptides or complexes with other chemicals combined with creatine. The creatine and insulin modulating substance such as L-arginine are preferably in sustained-release form so as to modulate and facilitate the absorption and transport of the creatine to muscle via increased vasodilation. The sustained-release combination of creatine monohydrate and L-arginine free base prolong the time period for muscle perfusion and enhance the supply of creatine to the muscles especially during extended athletic activity or body building. The arginine or giological equivalent, due to its endogenous anti-oxidant capacity via nitric oxide also serves to preserve creatine kinase which is oxidized by free radicals. Creatine kinase is responsible for converting creatine to phosphocreatine which is stored and recycled in muscles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU18008/01A AU1800801A (en) | 1999-11-17 | 2000-11-17 | Exercise and muscle enhancement formulations |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44193499A | 1999-11-17 | 1999-11-17 | |
| US09/441,934 | 1999-11-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001035953A2 WO2001035953A2 (en) | 2001-05-25 |
| WO2001035953A3 true WO2001035953A3 (en) | 2002-02-07 |
Family
ID=23754880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/032307 WO2001035953A2 (en) | 1999-11-17 | 2000-11-17 | Exercise and muscle enhancement formulations |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU1800801A (en) |
| WO (1) | WO2001035953A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004513877A (en) * | 2000-06-28 | 2004-05-13 | アンジオジェニックス，アイエヌシー． | Controlled release arginine preparation |
| DE10160485A1 (en) * | 2001-12-08 | 2003-10-02 | Degussa | Use of creatine and / or one of its physiologically suitable derivatives for the prevention or relief of non-disease-related impairments and / or disorders of muscle function |
| GB0518579D0 (en) * | 2005-09-12 | 2005-10-19 | Cr Technologies Llp | Controlled delivery creatine formulations and method of using the same |
| EP1859794A1 (en) * | 2006-04-24 | 2007-11-28 | Jeffrey M. Golini | Sustained release supplements |
| EP2027782A1 (en) * | 2007-08-15 | 2009-02-25 | Nestec S.A. | Increasing the efficiency of utilization of ingested creatine |
| CA2969860A1 (en) * | 2015-01-07 | 2016-07-14 | Corr-Jensen Inc. | Compositions and methods for enhancing athletic performance |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996018313A1 (en) * | 1994-12-17 | 1996-06-20 | The University Of Nottingham | Increasing creatine and glycogen concentration in muscle |
| US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
| WO1998043499A2 (en) * | 1997-04-01 | 1998-10-08 | Sigma-Tau Healthscience S.P.A. | Nutritional supplement |
| WO1999065476A2 (en) * | 1998-06-19 | 1999-12-23 | Bioenergy Inc. | COMPOSITIONS FOR INCREASING ENERGY $i(IN VIVO) |
-
2000
- 2000-11-17 WO PCT/US2000/032307 patent/WO2001035953A2/en active Application Filing
- 2000-11-17 AU AU18008/01A patent/AU1800801A/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
| WO1996018313A1 (en) * | 1994-12-17 | 1996-06-20 | The University Of Nottingham | Increasing creatine and glycogen concentration in muscle |
| WO1998043499A2 (en) * | 1997-04-01 | 1998-10-08 | Sigma-Tau Healthscience S.P.A. | Nutritional supplement |
| WO1999065476A2 (en) * | 1998-06-19 | 1999-12-23 | Bioenergy Inc. | COMPOSITIONS FOR INCREASING ENERGY $i(IN VIVO) |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001035953A2 (en) | 2001-05-25 |
| AU1800801A (en) | 2001-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barbul | Proline precursors to sustain mammalian collagen synthesis | |
| US7850997B2 (en) | Dietary compositions and methods of enhancing lean body mass and exercise performance | |
| RU2007143517A (en) | EXTERNAL USE FOR SKIN | |
| BRPI0519265A2 (en) | compositions including iron | |
| RU2001116855A (en) | APPLICATION OF BIOCHEMICAL SUBSTANCES IN A COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES CONDITIONS CAUSED BY THE REDUCTION OF SMOOTH MUSCLE CELLS IN HUMAN BODIES | |
| JP2015510888A5 (en) | ||
| ZA200706998B (en) | Salts, addition compounds and complex compounds of guanidinoacetic acid | |
| RS52129B (en) | Dietary supplement energy-providing to skeletal muscles and protecting the cardio vascular tract | |
| ATE536170T1 (en) | USE OF CATIONIC SURFACTANTS IN COSMETIC PRODUCTS | |
| BRPI0509418A (en) | acidic beverage composition and process for preparing a stable suspension of a proteinaceous material in an acidic beverage | |
| ZA201504103B (en) | Organ and tissue preservation formulations with increased stability and shelf life | |
| PT1195159E (en) | ASCORBATE THERAPEUTIC COMBINATION WITH LYSINE AND ARGININE FOR PREVENTION AND TREATMENT OF CANCER | |
| EA200700976A1 (en) | COMPOUNDS IN THE FORM OF MOLECULE-CONJUGATES, HAVING ENHANCED ACTIVITY WITH RESPECT TO THE INCLUSION OF CELL | |
| WO2001035953A3 (en) | Exercise and muscle enhancement formulations | |
| BR9808402B1 (en) | preservative solution, process for preserving food, and use of a preservative solution. | |
| MX2009012742A (en) | Novel active ingredient in cicatrization and use thereof. | |
| EP2229957A3 (en) | Stabilization of aqueous compositions of 18f-isotope labelled 2-fluoro-2-deoxy-d-glucose with ethanol | |
| DE60301878D1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ALPHA-KETOALKANIC ESTER OR AMID AND MILKY ACID OR MILKIC ACID SALT | |
| ES2527527T3 (en) | Branched chain amino acid based compositions to improve myocardial ventricular function in patients suffering from diabetes | |
| WO2004112511A3 (en) | Supplement for restoring growth hormone levels | |
| ES2225555T3 (en) | COMPOSITIONS OF APPROPRIATE AMINO ACIDS FOR THE TREATMENT OF CARDIAC INSUFFICIENCY. | |
| HK1109029A1 (en) | Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal | |
| DK1220678T3 (en) | Pharmaceutical preparations containing copper, salicylic acid and vitamin C | |
| MY150069A (en) | Formulation for prolonged release of active ingredients of medicaments | |
| Bryan | An Overview of Nitrite and Nitrate: New Paradigm of Nitric Oxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| 122 | Ep: pct application non-entry in european phase |